Zachary Roberts
Directeur Technique/Scientifique/R&D chez ALLOGENE THERAPEUTICS, INC.
Fortune : 89 209 $ au 30/06/2024
Profil
Zachary Roberts is currently the Chief Medical Officer & Executive Vice President at Allogene Therapeutics, Inc. He previously worked as the Director-Clinical Medical Research at Amgen, Inc. in 2015, the Vice President-Clinical Development at Kite Pharma, Inc. from 2018 to 2019, and the Chief Medical Officer at Instil Bio, Inc. from 2020 to 2022.
Dr. Roberts obtained his undergraduate degree from the University of Maryland and his doctorate from the University of Maryland School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 38 287 ( 0,02% ) | 89 209 $ | 30/06/2024 |
Postes actifs de Zachary Roberts
| Sociétés | Poste | Début |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 03/01/2023 |
Anciens postes connus de Zachary Roberts
| Sociétés | Poste | Fin |
|---|---|---|
| INSTIL BIO, INC. | Directeur Technique/Scientifique/R&D | 11/11/2022 |
| KITE PHARMA INC | Directeur Technique/Scientifique/R&D | 01/05/2019 |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | 01/07/2015 |
Formation de Zachary Roberts
| University of Maryland | Undergraduate Degree |
| University of Maryland School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
